ArticleJournal of translational medicine2026
Very long chain sphingolipids govern brain myelination by regulating oligodendrocyte differentiation and membrane microdomain integrity.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myelin Dynamics at the Axon-Oligodendrocyte Interface: Adaptive Conduction Homeostasis in Demyelination, Remyelination and White Matter Repair.International journal of molecular sciences · 2026Review
- Beyond Neurodegeneration: White Matter Vacuolation as a Primary Myelin Defect.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelin abnormalities, which have no effective treatment to-date, underlie numerous debilitating neurological disorders like Multiple Sclerosis (MS). While lipids constitute ~70% of myelin, the specific lipids critical for establishment of myelin sheath, and the mechanisms linking lipid metabolism to myelin assembly, have remained poorly defined, hindering therapeutic development.
methodsWe generated central nervous system-specific (cKO-nestin) and oligodendrocyte-specific (cKO-OL) conditional knockout mice for Ceramide Synthase 2 (CerS2), which synthesizes very long-chain (VLC; C22–C24) ceramides. A multi-omics approach combining lipidomics, proteomics, and high-resolution mass spectrometry imaging (MSI) was employed to delineate the lipid and protein aberrations upon CerS2 knockout. Functional consequences were assessed using behavioral tests, electron microscopy, and in vitro myelination assays of dorsal root ganglion (DRG) neuron-oligodendrocyte precursor cells (OPCs) co-cultures.
resultsCerS2 knockout mice exhibited severe neurological phenotypes, including convulsions, premature lethality, and profound hypomyelination. Lipidomics revealed pathological lipid remodeling marked by drastic depletion of VLC sphingolipids and compensatory increases in shorter-chain (C16–C18) ceramides—a lipid profile clinically relevant to MS. MSI confirmed VLC sphingolipid loss was localized to disrupted white matter tracts. Crucially, wild-type brain lipid extracts, but not those from CerS2-knockout mice, rescued oligodendrocyte differentiation and myelination in vitro. Mechanistically, VLC sphingolipid loss ablated membrane microdomains, displacing myelin basic protein (MBP) from lipid rafts that jeopardizes normal myelination. Pharmacological disruption of microdomains recapitulated the myelination failure.
conclusionOur findings define a novel pathogenic cascade where cell-autonomous loss of CerS2 impedes oligodendrocyte differentiation and depletes VLC sphingolipids, destabilizing membrane microdomains and impairing MBP localization, culminating in myelination failure. This work positions the CerS2-VLC sphingolipid axis as a potential therapeutic target for demyelinating diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.